Condition: Platinum-resistant Recurrent Ovarian Cancer · Sponsor: Shanghai Jiaolian Drug Research and Development Co., Ltd
To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
This description comes directly from the study's public registry record.
Xiaohua Wu · 0086-021-64175590 · JJYIN555@163.com
Always discuss trial participation with your own doctor first.
| Beijing Cancer Hospital | Beijing, China | Recruiting |
| The First Affiliated Hospital of Bengbu Medical University | Bengbu, China | Recruiting |
| XiangYa Hospital CentralSouth University | Changsha, China | Recruiting |
| Fujian Cancer Hospital | Fuzhou, China | Recruiting |
| Sun Yat-sen Memorial Hospital, Sun Yat-sen University | Guangzhou, China | Recruiting |
| Cancer Hospital of Shandong First Medical University | Jinan, China | Recruiting |
| Qilu Hospital of Shandong University | Jinan, China | Recruiting |
| Yunnan Cancer Hospital | Kunming, China | Recruiting |
| Guangxi Medical University Cancer Hospital | Nanning, China | Recruiting |
| Fudan University Shanghai Cancer center | Shanghai, China | Recruiting |
| The Obstetrics & Gynecology Hospital of Fudan University | Shanghai, China | Recruiting |
| The Second Hospital of Hebei Medical University | Shijiazhuang, China | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06434610